share_log

Guggenheim Maintains Buy on HilleVax, Lowers Price Target to $34

Benzinga ·  Nov 16, 2023 03:02

Guggenheim analyst Seamus Fernandez maintains HilleVax (NASDAQ:HLVX) with a Buy and lowers the price target from $38 to $34.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment